drugset

Drugs / insulin degludec/insulin aspart

Follow last change Apr 2013 re-read 2 minutes ago

insulin degludec/insulin aspart

also known as IDegAsp · NN5401

Developed for: type 2 diabetes mellitus
Investigated by: Novo Nordisk A/S

Trials 1 · a red edge is where a trial was stopped

today NCT01272193 · Ph 3

20112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT01272193	Jan → Sep 2011	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded

Press releases naming this drug 16 releases

Date	Issuer	Release
2013-01-21	Novo Nordisk A/S	Tresiba® (insulin degludec) og Ryzodeg® (insulin degludec/insulin aspart) får markedsføringstilladelse i Europa novonordisk.com ↗
2012-12-25	Novo Nordisk A/S	Ryzodeg® (insulin degludec/insulin aspart) approved in Japan novonordisk.com ↗
2012-12-25	Novo Nordisk A/S	Ryzodeg® (insulin degludec/insulin aspart) godkendt i Japan novonordisk.com ↗
2012-12-03	Novo Nordisk A/S	Ryzodeg® (insulin degludec/insulin aspart) passed review by First Committee on Drugs of Pharmaceutical Affairs in Japan novonordisk.com ↗
2012-12-03	Novo Nordisk A/S	Ryzodeg® (insulin degludec/insulin aspart) passerer evaluering i japansk medicinkomite novonordisk.com ↗
2012-11-08	Novo Nordisk A/S	Insulin degludec and insulin degludec/insulin aspart receive positive vote for approval from FDA Advisory Committee novonordisk.com ↗
2012-11-06	Novo Nordisk A/S	FDA offentliggør briefingmateriale forud for mødet i den rådgivende komite om insulin degludec og insulin degludec/insulin aspart novonordisk.com ↗
2012-11-06	Novo Nordisk A/S	FDA posts briefing materials prior to Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart novonordisk.com ↗
2012-10-25	Novo Nordisk A/S	FDA offentliggør fokus for mødet i den rådgivende komite om insulin degludec og insulin degludec/insulin aspart novonordisk.com ↗
2012-10-25	Novo Nordisk A/S	FDA discloses focus of Advisory Committee meeting on insulin degludec and insulin degludec/insulin aspart novonordisk.com ↗
2012-10-19	Novo Nordisk A/S	Novo Nordisk modtager positive udtalelser om Tresiba® (insulin degludec) og Ryzodeg® (insulin degludec/insulin aspart) fra de europæiske registreringsmyndigheder novonordisk.com ↗
2012-10-19	Novo Nordisk A/S	Tresiba® (insulin degludec) and Ryzodeg® (insulin degludec/insulin aspart) receive positive opinions from the European regulatory authorities novonordisk.com ↗
2012-07-18	Novo Nordisk A/S	Novo Nordisk A/S: FDA berammer møde i rådgivende komite om insulin degludec og insulin degludec/insulin aspart novonordisk.com ↗
2012-07-18	Novo Nordisk A/S	Novo Nordisk A/S: FDA schedules Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart novonordisk.com ↗
2012-06-08	Novo Nordisk A/S	Novo Nordisk A/S: FDA forlænger registreringssprocessen for insulin degludec og insulin degludec/insulin aspart med tre måneder novonordisk.com ↗
2012-06-08	Novo Nordisk A/S	Novo Nordisk A/S: FDA extends regulatory review period for insulin degludec and insulin degludec/insulin aspart by three months novonordisk.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	insulin degludec/insulin aspart	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01272193 ↗
Known as	IDegAsp	“This phase 3, 26-week, open-label, treat-to-target trial investigated the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) in” PMID 23557077 ↗ Apr 2013
Known as	NN5401	“The aim of this trial is to investigate the efficacy and safety of NN5401 (insulin degludec/insulin aspart) with insulin glargine in subjects with type 2 diabetes in Japan.” NCT01272193 ↗
Route	Subcutaneous	“Injected subcutaneously (under the skin) once daily prior to the largest meal of the day as monotherapy or combined with no more than 2 oral anti-diabetic drugs (OADs).” NCT01272193 ↗